10.24
전일 마감가:
$10.60
열려 있는:
$10.69
하루 거래량:
4.04M
Relative Volume:
1.01
시가총액:
$2.66B
수익:
$6.29B
순이익/손실:
$750.00M
주가수익비율:
3.5556
EPS:
2.88
순현금흐름:
$586.00M
1주 성능:
-6.82%
1개월 성능:
-2.20%
6개월 성능:
-12.10%
1년 성능:
-43.43%
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
OGN
Organon Co
|
10.24 | 2.76B | 6.29B | 750.00M | 586.00M | 2.88 |
![]()
LLY
Lilly Eli Co
|
845.72 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
![]()
JNJ
Johnson Johnson
|
189.69 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
231.24 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
![]()
NVS
Novartis Ag Adr
|
132.31 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
![]()
MRK
Merck Co Inc
|
86.40 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
2023-09-21 | 개시 | Barclays | Overweight |
2023-03-16 | 개시 | Raymond James | Outperform |
2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
2022-04-27 | 개시 | Goldman | Buy |
2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
2021-10-07 | 개시 | Piper Sandler | Neutral |
2021-09-01 | 개시 | BofA Securities | Buy |
2021-07-22 | 개시 | Citigroup | Buy |
2021-06-15 | 개시 | JP Morgan | Neutral |
2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Is There Now Opportunity in Organon Stock After Recent Double Digit Drop in 2025? - Yahoo
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Is Organon a Hidden Bargain After Shares Drop Nearly 40% in 2024? - simplywall.st
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Is Organon (NYSE:OGN) A Risky Investment? - 富途牛牛
Is Organon Co a good long term investmentInterest Rate Changes & Advanced Stock Screening Tools - earlytimes.in
3 Reasons To Avoid OGN And 1 Stock To Buy Instead - Barchart.com
User - FinancialContent
Organon (NYSE:OGN) Has No Shortage Of Debt - 富途牛牛
Organon & Co trades in the red for seven straight sessions - MSN
Organon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Co. (7XP) stock good for long term investingJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Organon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Organon & Co. $OGN Shares Purchased by State of Alaska Department of Revenue - MarketBeat
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know - Yahoo
Co. (7XP) stock in 2025Quarterly Profit Review & Community Driven Trade Alerts - newser.com
Organon & Co. $OGN Stake Lessened by Sound Income Strategies LLC - MarketBeat
Dakota Wealth Management Has $151,000 Stock Position in Organon & Co. $OGN - MarketBeat
Co. (7XP) stock considered safe havenPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Organon (OGN) Outperforms Broader Market: What You Need to Know - sharewise.com
What analysts say about Organon Co stockReal-Time Stock Alerts & High Return Stock Ideas - Early Times
Sterneck Capital Management LLC Makes New Investment in Organon & Co. $OGN - MarketBeat
Register Financial Advisors LLC Sells 30,706 Shares of Organon & Co. $OGN - MarketBeat
Organon partners across Asia Pacific to push equitable access to contraception ahead of World Contraception Day - MediaBrief
Here's Why Organon (OGN) Fell More Than Broader Market - sharewise.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Wedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN): Examining Valuation Following European Approval of Denosumab Biosimilars - simplywall.st
Organon announces departure of chief commercial officer - MSN
Gilman Hill Asset Management LLC Sells 443,231 Shares of Organon & Co. $OGN - MarketBeat
Triumph Capital Management Acquires 47,127 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Dips While Market Gains: Key Facts - sharewise.com
Organon gets EU approval for Prolia and Xgeva biosimilars - MSN
Douglas Lane & Associates LLC Raises Holdings in Organon & Co. $OGN - MarketBeat
Organon Q2 Preview: What to expect? - MSN
Ocugen gets EU approval for Prolia and Xgeva biosimilars - MSN
Organon (OGN) Gains EU Approval for Denosumab Biosimilars - GuruFocus
Organon gets EU approval for Prolia and Xgeva biosimilars (OGN:NYSE) - Seeking Alpha
Organon, Shanghai Henlius: EC approves marketing for Bildyos, Bilprevda - TipRanks
(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
Belpointe Asset Management LLC Buys New Stake in Organon & Co. $OGN - MarketBeat
Is Cognition Therapeutics Inc. stock heavily shortedMarket Performance Recap & Reliable Trade Execution Plans - خودرو بانک
WBI Investments LLC Purchases New Stake in Organon & Co. $OGN - MarketBeat
Profit Recap: Should I buy Organon Co stock nowGDP Growth & Low Risk High Win Rate Picks - خودرو بانک
Organon & Co. (OGN) Wins FDA Nod for Biosimilars to Prolia and Xgeva - Insider Monkey
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):